![Christine Siu](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Christine Siu
Director/Board Member at
MONTE ROSA THERAPEUTICS, INC.
Net worth: - $ as of 31/05/2026
Profile
Ms. Christine E. Siu is a Chief Operating Officer at BridgeBio Pharma, Inc. She is on the Board of Directors at Vividion Therapeutics, Inc. and Monte Rosa Therapeutics, Inc. Ms. Siu was previously employed as a Chief Financial & Accounting Officer by Eidos Therapeutics, Inc., a Chief Business Officer by The Bluefield Project to Cure Frontotemporal Dementia, a Senior Director-Operations & Business Development by Global Blood Therapeutics, Inc., a Principal by Third Rock Ventures LLC, a Vice President by Thomas, McNerney & Partners LLC, an Analyst by Bear, Stearns & Co., Inc., and a Portfolio Manager by Warburg Pincus LLC. She also served on the board at NeuroTherapeutics Pharma, Inc. She received her undergraduate degree from the University of Michigan and an MBA from Harvard Business School.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 11/06/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
Christine Siu active positions
| Companies | Position | Start |
|---|---|---|
| MONTE ROSA THERAPEUTICS, INC. | Director/Board Member | 01/12/2020 |
Vividion Therapeutics, Inc.
 Vividion Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology research company which develops precision therapeutics for cancers and immune disorders | Director/Board Member | 04/05/2021 |
Bright Peak Therapeutics AG
 Bright Peak Therapeutics AG BiotechnologyHealth Technology Develops immuno-oncology therapeutics | Director/Board Member | 10/06/2021 |
Bright Peak Therapeutics, Inc.
 Bright Peak Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops immunotherapies for the treatment of cancer and autoimmune diseases | Director/Board Member | - |
Former positions of Christine Siu
| Companies | Position | End |
|---|---|---|
| BRIDGEBIO PHARMA, INC. | Chief Operating Officer | 23/07/2024 |
| EIDOS THERAPEUTICS, INC. | Director of Finance/CFO | 31/12/2019 |
The Bluefield Project to Cure Frontotemporal Dementia
 The Bluefield Project to Cure Frontotemporal Dementia The Bluefield Project to Cure Frontotemporal Dementia is a non-profit organization focused on accelerating the development of treatments and finding a cure for frontotemporal dementia (FTD), a fatal early-onset brain disease primarily affecting people under 60. The private company is based in San Francisco, CA. The organization targets FTD caused by mutations in the progranulin gene (GRN), funding basic, translational, and clinical research through a consortium of academic institutions and fostering collaboration between scientists and clinicians. Key therapeutic priorities include increasing progranulin levels, reducing neuroinflammation, and improving lysosomal function and protein homeostasis. Bluefield also supports biomarker studies and patient registries to aid research and clinical trial enrollment. The company was founded by Richards Donohoe Robin. | Corporate Officer/Principal | 01/01/2017 |
| GLOBAL BLOOD THERAPEUTICS, INC. | Chief Operating Officer | 01/01/2014 |
Thomas, McNerney & Partners LLC
 Thomas, McNerney & Partners LLC Investment ManagersFinance TMT invests in companies located in the United States. The firm targets companies operating in the fields of life sciences and medical technology. It participates in restructuring transactions including spin-outs, roll ups and recapitalizations with an investment size of USD 5 - 40 million. | Private Equity Analyst | 31/12/2010 |
Training of Christine Siu
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
16
1st degree connections
15
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 15 |
|---|---|
Bear, Stearns & Co., Inc.
 Bear, Stearns & Co., Inc. Investment Banks/BrokersFinance Provides investment banking, securities trading and brokerage Services | Finance |
Warburg Pincus LLC
 Warburg Pincus LLC Investment ManagersFinance Warburg Pincus invests in companies located across the globe. The firm focuses on a broad range of sectors and industries. It provides financing for buyout transactions. | Finance |
University of Michigan
 University of Michigan Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Thomas, McNerney & Partners LLC
Thomas, McNerney & Partners LLC Investment ManagersFinance TMT invests in companies located in the United States. The firm targets companies operating in the fields of life sciences and medical technology. It participates in restructuring transactions including spin-outs, roll ups and recapitalizations with an investment size of USD 5 - 40 million. | Finance |
Third Rock Ventures LLC
 Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures invests in companies located in the United States. The firm targets companies operating in the fields of the healthcare sector. It provides financing for early stage capital requirements. It acts as a lead investor. | Finance |
NeuroTherapeutics Pharma, Inc.
 NeuroTherapeutics Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical and therapeutic drugs for central nervous system disorders | Health Technology |
Global Blood Therapeutics, Inc.
 Global Blood Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which provides treatment and care of sickle cell disease for inherited blood disorder | Health Technology |
Harvard Business School
 Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Bluefield Project to Cure Frontotemporal Dementia
The Bluefield Project to Cure Frontotemporal Dementia The Bluefield Project to Cure Frontotemporal Dementia is a non-profit organization focused on accelerating the development of treatments and finding a cure for frontotemporal dementia (FTD), a fatal early-onset brain disease primarily affecting people under 60. The private company is based in San Francisco, CA. The organization targets FTD caused by mutations in the progranulin gene (GRN), funding basic, translational, and clinical research through a consortium of academic institutions and fostering collaboration between scientists and clinicians. Key therapeutic priorities include increasing progranulin levels, reducing neuroinflammation, and improving lysosomal function and protein homeostasis. Bluefield also supports biomarker studies and patient registries to aid research and clinical trial enrollment. The company was founded by Richards Donohoe Robin. | |
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology research company which develops precision therapeutics for cancers and immune disorders | Health Technology |
Eidos Therapeutics, Inc.
 Eidos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company | Health Technology |
BridgeBio Pharma, Inc.
 BridgeBio Pharma, Inc. BiotechnologyHealth Technology Develops medicines for genetic diseases to patients | Health Technology |
Bright Peak Therapeutics AG
Bright Peak Therapeutics AG BiotechnologyHealth Technology Develops immuno-oncology therapeutics | Health Technology |
Monte Rosa Therapeutics, Inc.
 Monte Rosa Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops molecular glue degrader medicines for oncology, autoimmune and inflammatory diseases | Health Technology |
Bright Peak Therapeutics, Inc.
Bright Peak Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops immunotherapies for the treatment of cancer and autoimmune diseases | Health Technology |
- Stock Market
- Insiders
- Christine Siu
